Anti-hIL-31R-hIgG2
-
Cat.code:
hil31r-mab2
- Documents
ABOUT
Anti-human IL-31R (IL-31RA) - Nemolizumab biosimilar - CAS #1476039-58-3
Anti-hIL-31R-hIgG2 is a biosimilar antibody of Nemolizumab, a human interleukin 31 receptor A (IL-31RA) antibody that blocks IL-31 signaling. This monoclonal antibody (mAb), also known as anti-IL-31RA or anti-IL-31Rα, is FDA-approved for the treatment of prurigo nodularis (PN) and atopic dermatitis (AD).
Anti-hIL-31R-hIgG2 comprises the variable region of Nemolizumab and the IgG2 constant region of Nemolizumab for mild effector functions.
This mAb can be used together with HEK-Blue™ IL-31 cells for screening and neutralization assays to block IL-31R signaling induced by recombinant human IL-31 (see figure).
Key features
- Each lot is functionally tested and validated.
- The complete sequence of the antibody construct was verified.
- The absence of endotoxins is determined by the EndotoxDetect™ assay.
All products are for research use only, and not for human or veterinary use.
SPECIFICATIONS
Specifications
IL-31Rα, IL-31RA
Human
Sodium phosphate buffer with glycine, saccharose, and stabilizing agents
Negative (tested using EndotoxDetect™ assay)
Neutralization assay, ELISA
Each lot is functionally tested and validated.
CONTENTS
Contents
-
Product:Anti-hIL-31R-hIgG2
-
Cat code:hil31r-mab2
-
Quantity:100 µg
Shipping & Storage
- Shipping method: Room temperature
- -20 °C
- Avoid repeated freeze-thaw cycles
Storage:
Caution:
Details
Nemolizumab and IL-31 background
Nemolizumab (formally known as CIM331) is a humanized IgG2 monoclonal antibody (mAb) that blocks interleukin 31 (IL-31) signaling by targeting the IL-31 receptor A (IL-31RA or IL-31Rα) [1].
IL‐31, a member of the type I/II cytokine receptor family, is often referred to as the "itchy" cytokine [2]. Its binding to IL-31RA triggers the activation of the JAK/STAT, Akt/PI3K, and MAPK signaling pathways [2,3]. Little is known about the physiological function of IL-31. It is mainly secreted by IL-4-activated T cells, thereby contributing to Th2-weighted inflammation [2,3]. Several reports indicate that IL-31 is a pruritogenic cytokine that is highly implicated in disorders such as atopic dermatitis, asthma, and inflammatory bowel disease [2,3]. Thus, targeting the IL-31 pathway is a promising therapeutic option for dermatologic and non-dermatologic diseases with enhanced IL-31 expression [2,3].
Nemolizumab, marketed as Nemluvio®, received FDA approval in 2024 for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis, a chronic skin condition [4].
References:
1. Nemoto O, et al., 2016. The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study. Br J Dermatol. 174(2):296-304.
2. Datsi A., et al., 2021. Interleukin-31: The “itchy” cytokine in inflammation and therapy. Allergy. 76:2982-97.
3. Bagci I.S. and Ruzicka, T., 2018. IL-31: A new player in dermatology and beyond. J. Allergy Clin Immunol. 141(3):858-866.
4. U.S. Food and Drug Administration (FDA) (Report). 2024. New Drug Therapy Approvals 2024.
DOCUMENTS
Documents
Technical Data Sheet
Validation Data Sheet
Safety Data Sheet
Certificate of analysis
Need a CoA ?
